Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
106M
-
Number of holders
-
184
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
+551K
-
Total reported value, excl. options
-
$1.37B
-
Value change
-
+$17.2M
-
Put/Call ratio
-
0.04
-
Number of buys
-
90
-
Number of sells
-
-86
-
Price
-
$13.60
Significant Holders of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS) as of Q3 2025
222 filings reported holding RCUS - Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share as of Q3 2025.
Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS) has 184 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
of 106M outstanding shares and own 95.21% of the company stock.
Largest 10 shareholders include GILEAD SCIENCES, INC. (31.4M shares), BlackRock, Inc. (11.8M shares), VANGUARD GROUP INC (6.63M shares), Point72 Asset Management, L.P. (4.33M shares), Woodline Partners LP (3.77M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (3.69M shares), STATE STREET CORP (3.39M shares), Siren, L.L.C. (2.91M shares), FMR LLC (2.3M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.6M shares).
This table shows the top 184 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.